ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,996.66
1.00%
US Tech 100
20,877.20
1.72%
다우존스 지수
43,487.83
0.78%
Bitcoin
105,019.88
0.57%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Cardiol Therapeutics Inc (CRDL) 시세

Cardiol Therapeutics Inc

Cardiol Therapeutics Inc (CRDL)

Cordel Group Plc
Cardiol Therapeutics Inc
1.21
0.00
(0.00%)
마감 19 1월 6:00AM
15분 지연
1.19
-0.02
(-1.65%)
시간외 거래: 8:38AM
15분 지연

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

주요 통계 및 세부정보

가격
1.19
매수가
1.21
매도가
1.28
거래량
212,471
1.19 일간 변동폭 1.2161
0.9595 52주 범위 3.12
market_cap
97.108M
전일 종가
1.21
개장가
1.21
최근 거래 시간
2
@
1.2
마지막 거래 시간
재정 규모
US$ 255,765
VWAP
1.2038
평균 볼륨(3m)
377,688
발행 주식
81,603,422
배당수익률
-
주가수익률
-5.08
주당순이익(EPS)
-0.34
매출
-
순이익
-28.13M

Cardiol Therapeutics Inc 정보

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solut... Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. 더 보기

섹터
Coml Physical, Biologcl Resh
산업
Coml Physical, Biologcl Resh
본부
Oakville, Ontario, Can
설립됨
-
Cardiol Therapeutics Inc is listed in the Coml Physical, Biologcl Resh sector of the 나스닥 with ticker CRDL. The last closing price for Cardiol Therapeutics was US$1.21. Over the last year, Cardiol Therapeutics shares have traded in a share price range of US$ 0.9595 to US$ 3.12.

Cardiol Therapeutics currently has 81,603,422 shares in issue. The market capitalisation of Cardiol Therapeutics is US$98.74 million. Cardiol Therapeutics has a price to earnings ratio (PE ratio) of -5.08.

CRDL 최신 뉴스

추가 뉴스

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics...

19 12월 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

19 11월 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

15 11월 2024
Edgar (US Regulatory)

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL...

13 11월 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

22 10월 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

12 10월 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

11 10월 2024
Edgar (US Regulatory)

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

10 10월 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

10 10월 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

09 10월 2024
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.12-9.160305343511.311.311.172575331.24543764CS
4-0.25-17.36111111111.441.511.173028481.29518576CS
12-0.7-37.0370370371.892.241.173776881.56819521CS
26-1.01-45.90909090912.22.631.173914061.82464065CS
520.1716.66666666671.023.120.95954204621.89545883CS
156-0.98-45.16129032262.173.120.452724561.53068197CS
260-1.44-54.7528517112.634.960.453330472.02063445CS

CRDL - Frequently Asked Questions (FAQ)

What is the current Cardiol Therapeutics share price?
The current share price of Cardiol Therapeutics is US$ 1.19
How many Cardiol Therapeutics shares are in issue?
Cardiol Therapeutics has 81,603,422 shares in issue
What is the market cap of Cardiol Therapeutics?
The market capitalisation of Cardiol Therapeutics is USD 98.74M
What is the 1 year trading range for Cardiol Therapeutics share price?
Cardiol Therapeutics has traded in the range of US$ 0.9595 to US$ 3.12 during the past year
What is the PE ratio of Cardiol Therapeutics?
The price to earnings ratio of Cardiol Therapeutics is -5.08
What is the reporting currency for Cardiol Therapeutics?
Cardiol Therapeutics reports financial results in CAD
What is the latest annual profit for Cardiol Therapeutics?
The latest annual profit of Cardiol Therapeutics is CAD -28.13M
What is the registered address of Cardiol Therapeutics?
The registered address for Cardiol Therapeutics is 2265 UPPER MIDDLE ROAD EAST, SUITE 602, OAKVILLE, ONTARIO, L6H 0C3
Which industry sector does Cardiol Therapeutics operate in?
Cardiol Therapeutics operates in the COML PHYSICAL, BIOLOGCL RESH sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

CRDL Discussion

게시물 보기
Monksdream Monksdream 4 주 전
CRDL, under $2
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL SHORT SQUEEZE ALERTS

Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL

Cardiol Therapeutics MAvERIC-Pilot Study Results:

Safety: High tolerability and 95% compliance.

Next Steps: Data supports advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
👍️0
MahinAgency MahinAgency 2 월 전
A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL

Advancement: Results support Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials, expanding accessibility to non-immunosuppressive oral therapy.

Short Squeeze Alerts $CRDL, BIG OPPORTUNITY
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL

Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL Pick Up This Morning Short Sueeze Aler

 MAvERIC-Pilot Results:
Safety: High tolerance, 95% compliance.
Next Steps: Advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL MAvERIC-Pilot Study:

Efficacy: Significant reductions in pericarditis pain (mean score 5.8 to 1.5) and inflammation (CRP normalized in 80% of patients). Episodes dropped from 5.8/year to 0.9 during the trial.

👍️0
MahinAgency MahinAgency 2 월 전
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
👍️0
MahinAgency MahinAgency 2 월 전
INSIDER BUYING : Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
👍️0
MahinAgency MahinAgency 2 월 전
$CRDL Here are the MAvERIC-Pilot study results that we’ve been waiting for! 

❤️Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week study!

❤️Episodes of pericarditis per year substantially reduced 

❤️MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2
and the Phase III MAVERIC-3 clinical trials

Congratulations to all long term shareholders! 
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL BIG NEWS:

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
👍️0
MahinAgency MahinAgency 2 월 전
Breaking News: NASDAQ: $CRDL unveils groundbreaking results for CardiolRx™ at the American Heart Association Conference! 📷 Rapid pain relief, 85% fewer recurrences, and lasting inflammation reduction.
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Valued at $9 per share, assuming $609M in sales

Valued at $1 per share, assuming $132M in sales
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL RED TO GREEN, Looks Good

Cardiol Therapeutics Inc Today at 11:15am EST Dr. Allen Luis MayoClinic will present the Pericarditis full clinical data at #AHA2024
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL SHORT SQUEEZE ALERTS, STAY TUNED

Addressing urgent unmet medical needs: CardiolRx™ targets acute myocarditis, a life-threatening condition with no FDA-approved treatments
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

 Valued at $9 per share, assuming $609M in sales by 2033

Valued at $1 per share, assuming $132M in sales by 2033
👍 1
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

Recently raised $13.5 million to fund developments?, SHORT SQUEEZE ALERTS
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL lets See Red To Green, 

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

The company recently raised $13.5 million
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL The company recently raised $13.5 million, ensuring financial backing for ongoing clinical developments and corporate growth
👍️0
MahinAgency MahinAgency 2 월 전
Picked up NASDAQ: $CRDL this morning…low float runner on news incoming… Short Squeeze Alerts

The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis
👍️0
tw0122 tw0122 2 월 전
30 million shares offering at .26 October 30th
👍️0
MahinAgency MahinAgency 2 월 전
H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
👍️0
MahinAgency MahinAgency 2 월 전
$CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL SHORT SQUEEZE ALERTS

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price,aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 2 월 전
Key Points:

Rating & Price Target: H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.
New Trial: MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis (RP) patients post-IL-1 blocker therapy.
Market Advantage: CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.
Strategic Expansion: By targeting unmet needs in the RP market, CardiolRx is positioned to broaden its market potential.
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

Recently raised $13.5 million to fund developments?
👍️0
MahinAgency MahinAgency 2 월 전
Big coming Next week 💃💃💃💃
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL
ARCHER trial completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales 

Promising early results, potential approval by 2027, targeting $609M peak sales

👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60

$CRDL BIG SHORT SQUEEZE 
👍️0
tw0122 tw0122 2 월 전
Chart looking good $2.07 next targets $4
👍️0
glenn1919 glenn1919 2 월 전
CRDL........................https://stockcharts.com/h-sc/ui?s=CRDL&p=W&b=5&g=0&id=p86431144783
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Cardiol had around $21 million in cash at the end of Q1 


👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL
 Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis.

The 12-month price target is $10
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL CEO Investment: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
👍️0
MahinAgency MahinAgency 2 월 전
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 3 월 전
NASDAQ: $CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

👍️0
MahinAgency MahinAgency 3 월 전
NASDAQ: $CRDL A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 3 월 전
Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 3 월 전
$CRDL Insider Buying: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each
👍️0
MahinAgency MahinAgency 3 월 전
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities
👍️0
MahinAgency MahinAgency 3 월 전
NASDAQ: $CRDL 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

👍️0
MahinAgency MahinAgency 3 월 전
NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

Cardiol sets a 12-month price target of $10
👍️0
MahinAgency MahinAgency 3 월 전
NASDAQ: $CRDL Short Squeeze Allerts 

A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 3 월 전
Volume looks GOOD 💃💃🚀
👍️0

최근 히스토리

NASDAQ
CRDL
Cardiol Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유